Literature DB >> 4040860

In vitro plasma binding of some second generation antitumor platinum complexes.

R Momburg, M Bourdeaux, M Sarrazin, F Roux, C Briand.   

Abstract

The kinetics of five cisplatin analogs binding to human plasma fractions possessing a molecular weight greater than 50,000 daltons were studied. Each drug solution in plasma ultrafiltrate or phosphate buffer (pH = 7.4, mu = 0.154) was mixed with human plasma and filterable platinum concentrations were measured versus time by atomic absorption spectrophotometry. The only Pt IV compound studied did not bind. All the other Pt II complexes bound, but their binding kinetics were quite different. The experimental data were fitted to a theoretical equation based on the hypothesis that plasma nucleophilic agents possessing a molecular weight greater than 50,000 daltons are able to react with Pt compounds with an apparent second order rate constant. The apparent reaction rate constants and initial concentrations of these nucleophilic agents were calculated. The difference between the respective values obtained for each cisplatin analog could be explained by differences in their chemical formulas. Therefore our result should contribute towards a better understanding of the pharmacokinetics of the cisplatin analogs studied.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040860     DOI: 10.1007/BF03189700

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  Platinum compounds: a new class of potent antitumour agents.

Authors:  B Rosenberg; L VanCamp; J E Trosko; V H Mansour
Journal:  Nature       Date:  1969-04-26       Impact factor: 49.962

2.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man.

Authors:  T F Patton; K J Himmelstein; R Belt; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1978-09

3.  Structure-activity relationships of the antitumor platinum coordination complexes.

Authors:  T A Connors; M J Cleare; K R Harrap
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

4.  Measurement of free-circulating cis-dichlorodiammineplatinum(II) in plasma.

Authors:  S J Bannister; L A Sternson; A J Repta; G W James
Journal:  Clin Chem       Date:  1977-12       Impact factor: 8.327

Review 5.  Clinical pharmacology and pharmacokinetics of cis-platinum and analogs.

Authors:  P Ribaud; J Gouveia; M Bonnay; G Mathe
Journal:  Cancer Treat Rep       Date:  1981

6.  Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs.

Authors:  A W Prestayko; W T Bradner; J B Huftalen; W C Rose; J E Schurig; M J Cleare; P C Hydes; S T Crooke
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

7.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.

Authors:  L Pendyala; W Greco; J W Cowens; S Madajewicz; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.

Authors:  H Sharma; N Thatcher; J Baer; A Zaki; A Smith; C A McAucliffe; D Crowther; S Owens; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more
  8 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

Authors:  W J van der Vijgh; I Klein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.

Authors:  R C Gaver; A M George; G Deeb
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.

Authors:  C Fournier; B Hecquet; G Bastian; D Khayat
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Studies on the human metabolism of iproplatin.

Authors:  L Pendyala; B S Krishnan; J R Walsh; A V Arakali; J W Cowens; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

7.  Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions.

Authors:  H J Guchelaar; D R Uges; P Aulenbacher; E G de Vries; N H Mulder
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

8.  Comparative intraperitoneal pharmacokinetics of three platinum analogues.

Authors:  M J Lind; D J Murphy; H Sharma; N Tinker; A Smith; C A McAuliffe; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.